JERINI

Management Board and Supervisory Board Decide to Wind Down the Operations of Jerini Ophthalmic, Inc.

Ad-hoc Announcement pursuant to § 15 German Securities Trading Act (WpHG) - mandatory information for Europe-wide distribution


Berlin, April 24, 2009 – Jerini AG's Supervisory Board approved today the Management Board's decision of today to wind down the operations of Jerini Ophthalmic, Inc., New York, USA, a subsidiary of Jerini AG. The decision was taken following unsuccessful efforts to find an investor for the sale of Jerini Ophthalmic, Inc.  Given the substantial investments required and the Company’s interests,  a continuation of Jerini Ophthalmic, Inc.'s operations would be unjustified.  The decision to wind down the operations of Jerini Ophthalmic, Inc. is expected to entail impairments of investments on the level of Jerini AG of up to EUR 6.8 million. The costs of closing the operations of Jerini Ophthalmic, Inc. are presently expected to amount to approximately EUR 1.4 million.

Jerini AG
The Management Board

ISIN: DE0006787476
WKN: 678 747
Regulated Market / Prime Standard; Frankfurt Stock Exchange, Germany
Registered Office: Berlin, Germany

For questions, please contact:
Stacy Wiedenmann
Director Investor Relations &
Corporate Communications
Jerini AG
Invalidenstr. 130
10115 Berlin
T  + 49 - 30 - 97893 - 285
X  + 49 - 30 - 97893 - 105
wiedenmann@jerini.com